🔎 Trials Near Me

Beranda › Penyakit Autoimun › Massachusetts › Boston

Uji klinis Penyakit Autoimun di Boston, MA

13 studi untuk Penyakit Autoimun mencari peserta di lokasi sekitar Boston (dalam radius sekitar 30 mil). Buka studi untuk melihat kriteria peserta dan cara menghubungi tim studi.

Teks studi resmi (Bahasa Inggris)

Merekrut peserta untuk studi di sini? Tampilkan di bagian atas halaman ini — $99 selama 30 hari →

Two Arm, Double-blind, Phase III Study Assessing Efficacy and Safety of Ianalumab Versus Placebo, in Participants With Sjögren's Disease With High Symptom Burden

Menerima pesertaFase 3
  • Tufts Medical Center, Boston
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 28 Sep 2026 · NCT07621809

Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO

Menerima pesertaFase 1
  • Massachusetts General Hospital Cancer Center, Boston
  • Dana-Farber Cancer Institute, Boston
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 23 Sep 2026 · NCT03816345

A Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia

Menerima pesertaFase 3
  • Massachusetts General Hospital, Boston
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 18 Sep 2026 · NCT06722235

RESET-Myositis: An Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Idiopathic Inflammatory Myopathy or Juvenile Idiopathic Inflammatory Myopathy

Menerima pesertaFase 2/3
  • Boston Children's Hospital - Accepting Young Adults and Juvenile Patients, Boston
Usia 6 hingga 75 · Semua jenis kelamin · Diperbarui 17 Sep 2026 · NCT06154252

A Follow-up Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia

Menerima pesertaFase 3
  • Massachusetts General Hospital, Boston
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 9 Sep 2026 · NCT06948318

RESET-SLE: A Phase 1/2 Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Systemic Lupus Erythematosus

Menerima pesertaFase 1/2
  • Tufts Medical Center, Boston
  • Massachusetts General Hospital, Boston
  • Boston Children's Hospital, Boston
  • dan 1 lainnya
Usia 18 hingga 65 · Semua jenis kelamin · Diperbarui 26 Agu 2026 · NCT06121297

RESET-MG: A Study to Evaluate the Safety and Efficacy of CABA-201 in Participants With Generalized Myasthenia Gravis

Menerima pesertaFase 1/2
  • Beth Israel Deaconess Medical Center, Boston
Usia 18 hingga 70 · Semua jenis kelamin · Diperbarui 13 Agu 2026 · NCT06359041

A Study of Mavorixafor in Participants With Congenital and Acquired Primary Autoimmune and Idiopathic Chronic Neutropenic Disorders Who Are Experiencing Recurrent and/or Serious Infections

Menerima pesertaFase 3
  • Boston Children's Cancer Center, Boston
Usia 12 ke atas · Semua jenis kelamin · Diperbarui 6 Agu 2026 · NCT06056297

A Study of Healthy Donor CD19-targeted Allogeneic CAR T Cells in Participants With Severe, Refractory Autoimmune Diseases

Menerima pesertaFase 1
  • Brigham And Womens Hospital, Boston
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 14 Jul 2026 · NCT07115745

A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)

Menerima pesertaStudi observasional
  • Tufts Medical Center, Boston
  • Beth Israel Deaconess, Boston
  • Dana Farber Cancer Institute, Boston
Semua usia · Semua jenis kelamin · Diperbarui 6 Jul 2026 · NCT01351545

Study of Single Doses of SBT777101 in Subjects With Rheumatoid Arthritis

Menerima pesertaFase 1
  • Tufts University, Boston
  • Massachusetts General Hospital, Boston
  • Brigham and Women's Hospital, Boston
Usia 18 hingga 70 · Semua jenis kelamin · Diperbarui 30 Jun 2026 · NCT06201416

Testimonials and Navigation in Rheumatology

Menerima peserta
  • Brigham Women's Hospital, Boston
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 6 Mei 2026 · NCT06469788

Uji klinis Penyakit Autoimun di kota lain

Studi lain di Boston

Dari ClinicalTrials.gov, data diambil 5 Okt 2026. Setiap studi menetapkan kriteria kelayakannya sendiri; tim studi yang menentukan siapa yang bisa bergabung.